glp-1 drugs pharmaceutical companies news 2025 Retailers across the country are noticing a spike in returns of clothing as more Americans embrace for weight loss. The rate of retail exchanges where shoppers traded clothing for a GLP-1 Market Trends | Whitepaper

A., & Bentez-Porres, J

About ATTAIN-MAINTAIN trial and ATTAIN clinical trial program ATTAIN-MAINTAIN (NCT06584916) was a 52-week, Phase 3, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of once-daily orforglipron versus placebo for maintenance of body weight reduction in adults with obesity or overweight with weight-related comorbidities who previously completed the SURMOUNT-5 head-to-head trial

But GLP-1 receptor agonists (sometimes written as GLP-1 RAs) are not a new miracle solution for shedding extra belly fat

a There is significant heterogeneity for FBG (I 2 = 88.5%), Insulin (I 2 = 96.5%), HbA1C (I 2 = 90.5%) and HOMA-IR (I 2 = 98.1)